Immune Responses to rAAV Gene Therapy

Several recombinant adeno-associated virus (rAAV) vectors are now approved for human use in the US, Europe, and other nations around the world. Yet, a variety of different types of innate and adaptive immune responses continue to limit this therapeutic platform’s ability to live up to its full potential for safe and effective gene transfer. Human Gene Therapy is now seeking original papers describing various aspects of this problem and their potential solutions. This could include, but is not limited to, the following:

• Mechanisms of rAAV-vector-related complement activation, toll-like receptor activation and other arms of innate immunity
• Adaptive immune responses to both AAV capsid proteins and transgene products, including both humoral and cell-mediated immunity
• Special features of immune responses to rAAV gene therapy based on specific routes of delivery or other protocol-specific features
• Strategies to mitigate immune responses including both immunosuppressive medication regimens, induction or augmentation of regulatory T cells, and innovative vector formulations

Manuscript submission deadline: November 1, 2023.

Benefits of publishing with Human Gene Therapy include:

• No submission fees
• Latest Impact Factor: 4.2
• Average time to first decision: 21 days
• Expert peer review and editorial oversight of your manuscript from leading specialists in your field
• Zero-embargo Green Open Access policy
• Immediate deposit of your work to PubMed and other indexing services upon publication
• Free 30-day access to share your published research with your networks and colleagues
• Global visibility in more than 170 countries  

Visit the journal website to view more on information for authors including manuscript guidelines, information on available author services, and publication costs.

Please direct inquiries to Dr. Ertl or the Managing Editor of Human Gene Therapy, Dr. Thomas Gallagher.